Elanco Animal Health (ELAN) Tops Q3 EPS by 4c, Revenues Miss; Offers FY18 EPS Outlook Above Consensus,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Elanco Animal Health Reports Strong Third Quarter Results, Provides Financial Guidance for Full Year 2018
November 6, 2018 6:02 AM ESTThird quarter revenue grew 9 percent to $761.1 million. Revenue, excluding strategic exits, grew 13 percent to $733.4 million; removing the impact of foreign currency exchange rates, growth was 15 percent. Reported net income grew $80.9 million in the third quarter to $60.2 million, which represents $0.16 per diluted share and $0.29 per diluted share on an adjusted basis. Delivered Innovation, including launching Prevacent® PRRS, a swine vaccine, and CorrelinkTM, a nutritional health product for poultry, as well as signing a licensing agreement with Novozymes to... More
